Reminyl, Galantamine

Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 20 of 26 in Reminyl, Galantamine (generic)

  1. Pharmacological Dissociation of Novelty Responses in the Human BrainRead the original story

    Monday Apr 7 | Cerebral Cortex

    Address correspondence to Dr Nico Bunzeck, Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.

    Comment?

  2. Impaired working memory by repeated neonatal MK-801 treatment is...Read the original story

    Mar 13, 2014 | CiteULike

    European journal of pharmacology , Vol. 725 , pp. 32-39, doi:10.1016/j.ejphar.2014.01.007 Early life blockade of the NMDA receptor by using MK-801, a non-competitive NMDA receptor antagonist, induces behavioral changes that mimic several features of schizophrenia.

    Comment?

  3. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex.Read the original story

    Mar 13, 2014 | CiteULike

    The tryptophan metabolite kynurenic acid is an endogenous antagonist of the I 7 nicotinic acetylcholine receptor and, at higher concentrations, inhibits ionotropic glutamate receptors.

    Comment?

  4. Impaired working memory by repeated neonatal MK-801 treatment is...Read the original story

    Feb 11, 2014 | CiteULike

    Early life blockade of the NMDA receptor by using MK-801, a non-competitive NMDA receptor antagonist, induces behavioral changes that mimic several features of schizophrenia.

    Comment?

  5. Alzheimer's Disease Therapeutics Market to 2019 - Early Stage...Read the original story

    Jan 22, 2014 | Sys-Con Media

    Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation Summary GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation".

    Comment?

  6. Vitamin E may delay decline in mild-to-moderate Alzheimer's diseaseRead the original story w/Photo

    Dec 31, 2013 | Science Daily

    These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.

    Comment?

  7. Vitamin E may slow Alzheimer's progressionRead the original story

    Jan 3, 2014 | PakTribune

    ISLAMABAD: Scientists have for the first time found that Vitamin E may slow functional decline - problems with everyday tasks such as shopping, cooking and travelling - in patients with mild-to-moderate Alzheimer's.

    Comment?

  8. Vitamin E slows progress of Alzheimer's diseaseRead the original story w/Photo

    Jan 1, 2014 | Channel3000

    For nearly a decade Dr. Sanjay Asthana has conducted a study looking for a way to slow the devastating effects of Alzheimer's disease.

    Comment?

  9. Vitamin E may delay decline in mild-to-moderate Alzheimer's Disease, study findsRead the original story w/Photo

    Jan 1, 2014 | KurzweilAI.net

    New research published online first in the Jan. 1 Journal of the American Medical Association suggests that alpha tocepherol , may slow functional decline - problems with daily activities such as shopping, preparing meals, planning, and traveling - in patients with mild-to-moderate Alzheimer's disease and decrease caregiver burden.

    Comment?

  10. New Study Shows That Vitamin E May Benefit Alzheimer's Patients in...Read the original story

    Dec 31, 2013 | PRWeb

    New research from the faculty of Icahn School of Medicine at Mount Sinai working with Veterans Administration Medical Centers suggests that alpha tocepherol, fat-soluble Vitamin E and antioxidant, may slow functional decline in patients with mild-to-moderate Alzheimer's disease and decrease caregiver burden.

    Comment?

  11. Vitamin E may delay decline in mild-to-moderate Alzheimer's diseaseRead the original story

    Dec 31, 2013 | Science Daily

    These issues are among the most taxing burdens of the disease for caregivers, which total about 5.4 million family members and friends.

    Comment?

  12. Study shows benefit in activities of daily living and savings in caregiver time with vitamin ERead the original story

    Dec 31, 2013 | PhysOrg Weblog

    Difficulty with activities of daily living often affect Alzheimer's patients, which is estimated to affect as many as 5.1 million Americans.

    Comment?

  13. Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022Read the original story

    Dec 26, 2013 | Sys-Con Media

    Summary GlobalData has released its new PharmaPoint Drug Evaluation report, "Razadyne/Reminyl - Forecast and Market Analysis to 2022".

    Comment?

  14. Antioxidant activity of galantamine and some of its derivatives.Read the original story

    Dec 8, 2013 | CiteULike

    Oxidative stress is implicated in the pathogenesis of different human diseases: Alzheimer, Parkinson, Huntington, amyotrophic lateral sclerosis , Down's syndrome, atherosclerosis, vascular disease, cancer, diabetes mellitus type 1 and type 2, age - related macular degeneration, psoriatic arthritis.

    Comment?

  15. Recent Study: Alzheimer's Disease Therapeutics Market to 2019Read the original story

    Dec 3, 2013 | PR-inside.com

    GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - ".

    Comment?

  16. Galantamine efficacy and tolerability as an augmentative therapy in...Read the original story

    Nov 25, 2013 | CiteULike

    The role of cholinergic abnormalities in autism was recently evidenced and there is a growing interest in cholinergic modulation, emerging for targeting autistic symptoms.

    Comment?

  17. Natural products as sources of new lead compounds for the treatment of Alzheimer's disease.Read the original story

    Nov 24, 2013 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  18. Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis ...Read the original story

    Nov 22, 2013 | SBWire

    GlobalData has released its new PharmaPoint Drug Evaluation report, "Razadyne/Reminyl - Forecast and Market Analysis to 2022".

    Comment?

  19. Alzheimer's Disease Therapeutics Market To 2019: Worldwide...Read the original story

    Nov 17, 2013 | PRWeb

    MarketResearchReports.Biz announces addition of new report, "Alzheimer's Disease Therapeutics Market To 2019" to its database.

    Comment?

  20. Life-Enhancement offers the Best High Quality Nutritional SupplementsRead the original story

    Nov 13, 2013 | PR Log

    Nov. 13, 2013 - MINDEN, Nev. -- Every product offered by Life Enhancement Products, Inc. contains only the highest quality and safest pharmaceutical- grade ingredients available in the world.

    Comment?